OOIR: Observatory of International Research

Papers

(The H4-Index of Antiviral Research is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Editorial Board	357
Editorial Board	97
RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination	96
Editorial Board	77
Editorial Board	63
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies	61
Corrigendum to “Crystal structure and cap binding analysis of the methyltransferase of langat virus” [Antivir. Res. 208 (2022) 105459]	59
A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy	58
Novel inhibitors of HSV-1 protease effective in vitro and in vivo	57
Long-term and efficient inhibition of hepatitis B virus replication by AAV8-delivered artificial microRNAs	55
Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study	54
A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN	51
Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier	45
Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells	43
Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro	42
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2	41
Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice	36
Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models	36
Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.	35
Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection	35
Berberine promotes K48-linked polyubiquitination of HNF4α, leading to the inhibition of HBV replication	35
A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies	34
Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses	33
Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals	33
JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase	33

The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection	32
Chemical-induced degradation of PreS2 mutant surface antigen via the induction of microautophagy	31
Novel strategy for Poxviridae prevention: Thermostable combined subunit vaccine patch with intense immune response	31
Corrigendum to “The novel therapeutic target and inhibitory effects of PF-429242 against Zika virus infection” [Antivir. Res. vol 192 (2021) 1–13/105121]	30
Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections	30